BN4003 l Version 2, entitled "A MULTICENTER, OPEN-LABEL, LONG-TERM EXTENSION OF PHASE ill STUDIES (BN29552/BN29553) OF CRENEZUMAB IN PATIENTS WITH ALZHEIMER'S DISEASE

StatusActive
Effective start/end date30/11/1830/11/21

Funding

  • Roche Diagnostics Corporation: $12,500.00

Keywords

  • Aging & Alzheimers, Biotechnology & Drug Development